Core Insights - The stock of Qiming Medical (02500) rose over 7%, reaching HKD 2.44 with a trading volume of HKD 4.5441 million following the announcement of mid-term clinical results for the Cardiovalve transcatheter tricuspid valve replacement system in the TARGET study [1] Group 1: Clinical Study Results - The TARGET study is a prospective, multi-center, single-arm clinical trial conducted across 25 centers in Germany, Spain, Italy, Canada, and the UK, involving 125 patients with an average age of 77 [1] - The average procedure time for the device was 58±29 minutes, with an intraoperative success rate of 88% and an implant success rate of 95% [1] - At the 6-month follow-up, 100% of patients had no moderate or severe regurgitation, with 88% showing improvement in heart function to NYHA class I/II, increasing to 90% at 12 months; quality of life scores improved by an average of 20 points, and 6-minute walking distances increased by 44 meters and 32 meters respectively [1] Group 2: Safety and Expert Recognition - The overall mortality rate was 6.4% (8 out of 125), with a heart failure readmission rate of 1.6%; the incidence of pericardial effusion, disabling stroke, and acute kidney injury requiring renal replacement therapy was low [2] - Qiming Medical highlighted that the mid-term clinical data for the Cardiovalve system, presented at the PCR London Valves 2025 conference, demonstrated the product's excellent clinical efficacy in treating severe tricuspid regurgitation, receiving high recognition from international clinical experts [2] - The company will continue to actively advance the global clinical registration and development process for innovative products, including the Cardiovalve system [2]
启明医疗-B涨超7% Cardiovalve三尖瓣置换系统中期临床显示安全及疗效良好